An Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Repeat Intramuscular ABP-450 (prabotulinumtoxinA) Injection for the Treatment of Cervical Dystonia
Latest Information Update: 26 Aug 2024
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Torticollis
- Focus Adverse reactions
- Sponsors AEON Biopharma
Most Recent Events
- 18 Jan 2024 Results presented in an AEON Biopharma media release.
- 18 Jan 2024 According to AEON Biopharma media release, the company presented new data from this study at TOXINS 2024, a leading conference held by the International Neurotoxin Association (INA) from January 17th - 20th at the Estrel Berlin in Berlin, Germany.
- 08 Aug 2023 Status changed from active, no longer recruiting to completed.